Trial Profile
A phase II study of TZ-101 in pediatric cancer patients undergoing cord blood stem cell transplantation for the treatment of hematologic alignancies
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2017
Price :
$35
*
At a glance
- Drugs TZ 101 (Primary)
- Indications Graft-versus-host disease; Haematological malignancies
- Focus Therapeutic Use
- 10 Mar 2017 New trial record
- 06 Mar 2017 According to a Targazyme media release, the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in the study.